The priMe Trial Gathers Momentum
We are thrilled to announce the annual meeting for the pivotal phase III trial , priMe, set to take place in Entebbe, Uganda on November 29-30, 2023. This collaborative effort…
moreRecap: SLS Europe at BioEurope and EDCTP Forum
Last week, SLS Europe was an active participant in two influential events: BioEurope 2023 in Munich and the Eleventh EDCTP Forum in Paris. Our goal was to gain the latest…
moreClinical trial results for SIIPL Tdap are online
The Phase II/III study, conducted in Germany, assessed the safety and immunogenicity of SIIPL Tdap, a novel booster vaccine for tetanus, diphtheria, and pertussis. This publication represents a significant step…
moreSLS Europe is attending the 11th EDCTP Forum
With the theme ‘Partnering for Global Health Research Innovation in Africa – Celebrating Two Decades of EDCTP,’ we’re excited to be part of this milestone event. The event will take…
moreWHO recommends R21/Matrix-M vaccine for malaria prevention
Serum Life Science Europe GmbH (SLS Europe) is delighted to announce the recommendation by the World Health Organization (WHO) for the novel R21/Matrix-M Malaria Vaccine for prevention of malaria in…
moreStefan Kaufmann Advocates for Advancements in Tuberculosis Control
Renowned vaccine researcher, Prof. Dr. Stefan H. E. Kaufmann, recently shared his expertise and insights on tuberculosis in an exclusive interview with ETHealthworld. Prof. Dr. Kaufmann, the inventor of VPM1002,…
moreREGISTRATION IS OPEN!
REGISTRATION IS OPEN! It is our pleasure to announce that the 14th International VPM Days will take place on Thursday and Friday, 28 and 29 September 2023 at TWINCORE in…
moreSAVE THE DATE!
SAVE THE DATE! Wir freuen uns, mitzuteilen, dass die 14. Internationalen VPM-Tage am Donnerstag und Freitag, 28. und 29. September 2023, im TWINCORE in Hannover stattfinden werden.
moreVPM helps facilitate fast track designation for Memo Therapeutics AG’s AntiBKV first-in-class treatment for BK virus infection in renal transplant recipients
VPM helps facilitate fast track designation for Memo Therapeutics AG’s AntiBKV first-in-class treatment for BK virus infection in renal transplant recipients Vakzine Projekt Management GmbH (VPM) announced today that it…
moreVPM contributes to the successful licensure of the novel malaria vaccine R21/Matrix-MTM for first use in Ghana
VPM contributes to the successful licensure of the novel malaria vaccine R21/Matrix-MTM for first use in Ghana. Vakzine Projekt Management GmbH (VPM) is delighted to announce the successful licensing of the…
more